Data protection Impressum

Oncology

The Institute of Life Technologies of the HES-SO Valais/Wallis has forged a five-year collaboration with Debiopharm Research & Manufacturing to develop new targeted antibody fragment vectorization technologies.

HES-SO Valais-Wallis and Debiopharm partner up to battle cancer

4 October 2023

Top Stories Western Switzerland

Top Stories from Western Switzerland (July-September 2023)

27 September 2023

The Vaud-based biotech start-up, ranking first in the TOP 100 Swiss Startup Award 2023, harnesses the dark genome to craft precise RNA therapies for disease-modifying cell states.

HAYA Therapeutics triumphs at the 13th TOP 100 Swiss Startup Award

11 September 2023

Backed by its parent company Nanobacterie's fourth-place in nanomedicine patent rankings by Marks and Clerk, AlphaOnco Swiss channels the synergy of Franco-Swiss collaboration to bring forth groundbreaking cancer treatments.

Nanomedicine pioneer Nanobacterie achieves remarkable patent ranking

23 August 2023

The canton of Bern, with its continual focus on advancing medicine through research, technology, and collaboration, stands as destination rich in opportunities for companies aiming to grow and innovate in the fields of medicine and life sciences.

Bern’s thriving ecosystem for life sciences innovation

9 August 2023

This discovery provides insight into the complex ecosystem of the tumor microenvironment and offers a new perspective on the treatment of cancer, particularly in the field of oncology.

UNIGE researchers lead breakthrough in understanding tumor growth

8 August 2023

Since its Observer Country status since December 2015, Switzerland has participated in over 20 multinational clinical trials and infrastructure projects under the ECRIN banner, including platform trials on COVID-19.

European clinical research infrastructure bolstered as Switzerland becomes ECRIN member

5 July 2023

Revolutionary mRNA vaccine against melanoma to be tested in Geneva

13 June 2023

Revolutionary breakthrough in prostate cancer treatment at the University of Bern

12 June 2023

Lonza boosts next-generation anticancer drugs with CHF 97 million investment in Visp

7 June 2023

1 2 3 4 5 6 7 8 9